

Arvuta iga peptiidi jaoks täpsed lahuse mahud, insuliiniühikud ja annuste arv viaali kohta.
Viaal, vesi ja annus on teada
Ühikud mõõdavad mahtu, mitte toimeainet. 10 IU = 0,10 ml. Mitu mg selles on, sõltub segust. Kalkulaator on selle sinu eest välja arvutanud.
Peaaegu kõik insuliinisüstlad on U-100. Vali U-40 ainult siis, kui süstal on tähistatud U-40.
Lingitud allikad viivad PubMedisse ja avanevad uuel vahelehel.
Tesamorelin is a synthetic analog of human growth hormone-releasing hormone (GHRH). It consists of the full 44 amino acids of native GHRH(1-44), with the N-terminus modified by a trans-3-hexenoic acid group. This modification protects the molecule from rapid enzymatic degradation by dipeptidyl peptidase-4 (DPP-4), substantially extending its biological stability compared to unmodified GHRH. Tesamorelin carries the research designation TH9507 and is known in the pharmaceutical literature under the trade name Egrifta.
Unlike ghrelin-type growth hormone secretagogues such as Ipamorelin, Tesamorelin acts directly on the GHRH receptor in the pituitary gland. It mimics the body's own signal that prompts the somatotroph cells of the pituitary to release growth hormone (GH). Tesamorelin therefore does not introduce growth hormone from outside the body — it amplifies the body's own, pulsatile GH production. This mechanism largely preserves the physiological feedback of the hypothalamic-pituitary axis, which distinguishes Tesamorelin from the direct administration of recombinant GH.
Tesamorelin has been studied most extensively in clinical trials of HIV-associated lipodystrophy, a condition characterized by an accumulation of visceral abdominal fat. The registration trials by Falutz and colleagues demonstrated a meaningful reduction in visceral adipose tissue, making Tesamorelin one of the few GHRH peptides with a robust human clinical dataset. In peptide research, it is discussed primarily for its targeted effect on the visceral fat depot and its well-characterized pharmacokinetics.
Tesamorelin exerts its biological effects through the GHRH receptor axis and the downstream GH-IGF-1 cascade. The key mechanisms can be summarized as follows:
In research settings, Tesamorelin is typically administered subcutaneously once daily, preferably in the evening to support nocturnal GH release. A slow titration ramp is not strictly required, but starting at the lower end of the dose range is a sensible precaution to observe tolerability, particularly potential fluid retention.
A common vial size is 20 mg. Adding 2 mL of bacteriostatic water gives a concentration of 10 mg/mL (10,000 mcg/mL).
At 1 mg per day, a 20 mg vial provides 20 days of dosing (10 days at 2 mg per day). The smaller 10 mg vial reconstituted with 2 mL yields 5 mg/mL (5,000 mcg/mL) and provides ten single 1 mg doses. Use the Tesamorelin calculator above to compute exact volumes for any vial size, reconstitution volume, and target dose.
Tesamorelin is administered subcutaneously into the subcutaneous fat layer, most commonly into the abdomen in the area around the navel. Injection sites should be rotated from day to day to avoid localized irritation and tissue hardening. A very short half-life of roughly 30 minutes means the peptide acts quickly and clears quickly, which is why consistent daily administration is important for a stable research protocol.
Tesamorelin is supplied as a lyophilized (freeze-dried) powder in sealed vials and must be reconstituted with bacteriostatic water (BAC water) before use. BAC water contains 0.9% benzyl alcohol, which inhibits microbial growth and extends the usable window of the reconstituted solution. Sterile water for injection is not suitable for multi-dose vials because it offers no preservative.
If the solution appears cloudy, discolored, or contains visible particulate matter, discard the vial and do not inject it.
Tesamorelin has been studied in controlled clinical trials lasting more than a year and showed an overall manageable tolerability profile. However, because its effects are mediated by enhanced growth hormone and IGF-1 activity, the observable effects are closely linked to the known actions of the GH axis. All use remains in the research domain.
At standard research doses, Tesamorelin was described as largely well tolerated in the registration trials. Nonetheless, given its effect on the endocrine GH axis, caution is warranted and consultation with a qualified healthcare provider is strongly recommended.
Tesamorelin belongs to the family of GHRH analogs and is closely related functionally to Sermorelin and CJC-1295 (no DAC). All three stimulate the same GHRH receptor but differ in stability and duration of action. Sermorelin corresponds to the shorter GHRH(1-29) fragment, CJC-1295 without DAC is a modified fragment with improved stability, and Tesamorelin is a fully stabilized GHRH(1-44) analog with the most extensive clinical evidence base for visceral fat reduction.
A widely used concept in research combines a GHRH analog with a GHRP (growth hormone releasing peptide) such as Ipamorelin. The two peptides act through distinct, complementary receptors:
Because such a combined stimulus places greater demand on the GH-IGF-1 axis, research protocols typically favor conservative doses, careful monitoring of glucose and IGF-1, and planned breaks.
Owing to its specific clinical profile — the targeted reduction of visceral adipose tissue — Tesamorelin is often used as a standalone compound in research rather than being stacked. Its clearly defined endpoint of visceral fat reduction makes it a readily studyable single peptide with unambiguous biomarkers such as IGF-1 and VAT measurement.
Research-grade Tesamorelin is available directly from BergdorfBio: Tesamorelin at BergdorfBio.
Tesamorelin is not growth hormone — it is a GHRH analog. It prompts the pituitary to release more of the body's own growth hormone, whereas HGH supplies the hormone directly from outside the body. The key difference lies in feedback: with Tesamorelin, the inhibitory action of somatostatin is preserved, so GH levels cannot rise without limit. In addition, the natural pulsatile secretion pattern of growth hormone is maintained, which is not the case with constant HGH administration.
The body's largest natural GH release occurs during the first hours of deep sleep. An evening injection of Tesamorelin is intended to amplify this physiological pulse rather than create an additional, off-rhythm GH surge. The very short half-life of roughly 30 minutes fits this concept well, since the signal remains tightly time-limited.
IGF-1, used as a biomarker, rises measurably within the first days to weeks. The structural changes — in particular the reduction of visceral adipose tissue — develop considerably more slowly. In the registration trials, significant changes in visceral abdominal fat were typically documented only after several months of continuous use.
Because growth hormone and insulin act in partly opposing ways, a high insulin level after a carbohydrate-rich meal dampens the GH response. Research protocols therefore often suggest spacing the injection some time away from the last large meal. With an evening administration before bed, this gap often arises naturally.
Growth hormone can reduce insulin sensitivity, so Tesamorelin can influence fasting blood glucose and glucose tolerance. In studies, these effects were generally moderate and dose-dependent. Monitoring glucose values is sensible for longer research protocols, particularly in individuals with pre-existing insulin resistance.
Tesamorelin does not act on the hypothalamic-pituitary-gonadal axis and does not suppress the body's own testosterone production. A classic PCT, of the kind common after androgenic compounds, is therefore not required. Because Tesamorelin merely amplifies the natural GHRH signal, the pituitary generally recovers after discontinuation without further intervention.
Yes. As a growth hormone-releasing factor and GH secretagogue, Tesamorelin falls under the WADA prohibited list and is banned in sport both in-competition and out-of-competition. Athletes subject to WADA-compliant testing should treat Tesamorelin as a prohibited substance and verify the applicable anti-doping rules before any use.
Some research protocols combine a GHRH analog and a GHRP in a single syringe immediately before injection. In general, however, it is safer to reconstitute each peptide individually and inject them separately, since their combined stability in solution is not well characterized. Separate injections at adjacent sites add minimal inconvenience and eliminate the risk of dosing errors.
BergdorfBio offers research-grade Tesamorelin with verified purity and concentration. View the product page: Buy Tesamorelin at BergdorfBio. All products are sold strictly for research purposes.
Medical Disclaimer: The information on this page is provided for educational and research purposes only. Within the context of this offering, Tesamorelin is not an approved drug or medical treatment and is sold strictly for research use. Nothing on this page constitutes medical advice, diagnosis, or a recommendation to use any specific compound. Always consult a qualified healthcare professional before beginning any peptide protocol. BergdorfBio assumes no liability for the use or misuse of the information presented here.
Pulbrist valmis süstlani viie sammuga. Ülalolev kalkulaator annab kogused automaatselt.
Lase viaalil ja veel jõuda toatemperatuurini. Pühi mõlemad kummikorgid alkoholilapiga.
Tõmba kalkulaatori soovitatud BAC-vee kogus suurema süstlaga.
Lase veel voolata mööda peptiidiviaali siseseina, ära pihusta seda otse pulbrile.
Keeruta viaali õrnalt, ära raputa. Pulber lahustub selgeks 1-2 minuti jooksul.
Tõmba insuliinisüstlaga täpselt arvutatud kriipsuni. Valmis.
Tavalised algväärtused orienteerumiseks. Iga rida avab selle peptiidi kalkulaatori.
| Peptiid | Kategooria | Tavaline annus | Viaalisuurused | BAC (algus) | Saadaval | Arvuta |
|---|---|---|---|---|---|---|
| VIP | Neuropeptiidide uurimine | - | 10 mg | 2 ml | Ainult kalkulaator | Arvuta |
| Retatrutide | GLP-1/GIP/GCG | 0,5-12 mg | 2 / 5 / 10 / 15 mg | 2 ml | Ainult kalkulaator | Arvuta |
| Cagrilintide | Amüliini analoog | - | 5 mg | 2 ml | Ainult kalkulaator | Arvuta |
| Semaglutide | GLP-1 | 0,25-2,4 mg | 2 / 5 / 10 mg | 2 ml | Ainult kalkulaator | Arvuta |
| Tirzepatide | GLP-1/GIP | 2,5-15 mg | 10 / 15 / 20 / 30 / 60 / 90 mg | 2 ml | Ainult kalkulaator | Arvuta |
| GHK-Cu | Vaskepeptiid | 1-4 mg | 10 / 20 / 50 mg | 5 ml | Ainult kalkulaator | Arvuta |
| AHK-Cu | Vaskepeptiid | - | 100 mg | 5 ml | Ainult kalkulaator | Arvuta |
| BPC-157 | Kudede taastamine | 0,2-0,5 mg | 2 / 5 / 10 mg | 2 ml | Ainult kalkulaator | Arvuta |
| TB-500 | Thymosin Beta-4 | 2-5 mg | 2 / 5 / 10 mg | 2 ml | Ainult kalkulaator | Arvuta |
| CJC-1295 (ilma DAC-ta) | GHRH analoog | 100-200 mcg | 2 / 5 / 10 mg | 2 ml | Ainult kalkulaator | Arvuta |
| Ipamorelin | GHRP | 200-300 mcg | 2 / 5 mg | 2 ml | Ainult kalkulaator | Arvuta |
| AOD-9604 | Rasvade ainevahetus | 250-500 mcg | 2 / 5 mg | 2 ml | Ainult kalkulaator | Arvuta |
| PT-141 | Bremelanotide | - | 2 / 5 / 10 mg | 2 ml | Ainult kalkulaator | Arvuta |
| MOTS-c | Mitokondriaalne | 5-10 mg | 5 / 10 mg | 2 ml | Ainult kalkulaator | Arvuta |
| Selank | Anksiolüütiline | 150-500 mcg | 2 / 5 / 10 mg | 2 ml | Ainult kalkulaator | Arvuta |
| SS-31 | Elamipretide | 0,1-1 mg | 5 / 10 mg | 2 ml | Ainult kalkulaator | Arvuta |
| Glow Stack | Stack | 0,5-2 mg | 70 mg | 3 ml | Ainult kalkulaator | Arvuta |
| Klow Stack | Stack | 0,5-2 mg | 55 mg | 3 ml | Ainult kalkulaator | Arvuta |
| Melanotan II | Melanokortiin | 100-1000 mcg | 5 / 10 mg | 2 ml | Ainult kalkulaator | Arvuta |
| Melanotan I | Melanokortiin | - | 5 / 10 mg | 2 ml | Ainult kalkulaator | Arvuta |
| Sermorelin | GHRH analoog | 50-300 mcg | 5 mg | 2 ml | Ainult kalkulaator | Arvuta |
| Tesamorelin | GHRH analoog | 1-2 mg | 10 / 20 mg | 2 ml | Ainult kalkulaator | Arvuta |
| Thymosin Alpha-1 | Tüümusepetiid | 0,8-3,2 mg | 1.6 / 5 / 10 mg | 1 ml | Ainult kalkulaator | Arvuta |
| Epithalon | Pikaajalisus | 2-10 mg | 10 / 20 / 50 mg | 2 ml | Ainult kalkulaator | Arvuta |
| KPV | Immuunsüsteem / barjäär | 100-1000 mcg | 5 / 10 mg | 2 ml | Ainult kalkulaator | Arvuta |
| HGH Fragment 176-191 | Metaboolne fragment | 100-500 mcg | 2 / 5 / 10 mg | 2 ml | Ainult kalkulaator | Arvuta |
| Semax | Kognitiivne | 100-1000 mcg | 10 / 30 mg | 2 ml | Ainult kalkulaator | Arvuta |
| N-Acetyl Semax | Kognitiivne | 100-1000 mcg | 5 / 10 mg | 2 ml | Ainult kalkulaator | Arvuta |
| Hexarelin | GHRP | 50-200 mcg | 2 / 5 mg | 2 ml | Ainult kalkulaator | Arvuta |
| GHRP-6 | GHRP | 50-300 mcg | 2 / 5 mg | 2 ml | Ainult kalkulaator | Arvuta |
| GHRP-2 | GHRP | 50-250 mcg | 2 / 5 mg | 2 ml | Ainult kalkulaator | Arvuta |
| DSIP | Uni | 50-500 mcg | 10 mg | 2 ml | Ainult kalkulaator | Arvuta |
| 5-Amino-1MQ | Metaboolne | 2,5-10 mg | 10 mg | 2 ml | Ainult kalkulaator | Arvuta |
| Pinealon | Uurimispeptiid | - | 10 mg | 2 ml | Ainult kalkulaator | Arvuta |
| Survodutide | GLP-1/glükagoon | - | 10 mg | 2 ml | Ainult kalkulaator | Arvuta |
| Kisspeptin-10 | KISS1R / GPR54 | - | 10 mg | 2 ml | Ainult kalkulaator | Arvuta |
| HGH 191AA | Kasvuhormoon | 1-5 mg | 10 mg | 1 ml | Ainult kalkulaator | Arvuta |
| NAD+ | Pikaajalisus / kofaktor | 100-500 mg | 1000 mg | 10 ml | Ainult kalkulaator | Arvuta |
Väärtused on mõeldud orienteerumiseks uurimiskontekstis ega asenda professionaalset nõuannet.
Kontsentratsiooni ja süstemahu õige arvutamine tundub tühine, kuid on kõige sagedasem veaallikas. Isegi 10 % suurune arvutusviga lahuse valmistamisel tähendab, et saad kas liiga vähe toimeainet või manustad kogemata üleannuse.
Lüofiliseeritud peptiide müüakse milligrammides ja need lahustatakse bakteriostaatilises vees (BAC-vesi). Peptiidi ja vee suhe määrab kontsentratsiooni ja sellest tuleneb, mitu ühikut insuliinisüstlale tõmbad. Insuliinisüstlaid gradueeritakse ühikutes, mitte milligrammides. Kalkulaator teeb selle ümberarvutuse ära, sealhulgas mõistlikkuse kontrolli kõige ohtlikuma vea vastu: mg ja mcg segiajamine.
Milligramm (mg) on ühik, milles lüofiliseeritud peptiide müüakse, näiteks „5 mg BPC-157". Mikrogramm (mcg) mõõdab üksikannust, näiteks „250 mcg süsti kohta". 1 mg = 1000 mcg. Kalkulaator teeb ümberarvutuse automaatselt ja hoiatab, kui sisestus tundub segiaetud olevat.
U-100 tähendab, et süstal on kalibreeritud 100 ühikule milliliitri kohta. 100 IU = 1 ml, seega 10 IU = 0,10 ml, sõltumata sellest, mis süstlas on. IU arvutus põhineb täpselt sellel seosel.
Palju peptiidi ja vähe vett teeb lahuse väga kontsentreerituks, mistõttu maht annuse kohta on tilluke ja raskesti loetav. Kasuta segamise abivahendit: see leiab veekoguse, millega tekib puhas ja hästi loetav kriips.
Külmkapis 2-8 °C juures tavaliselt 21-30 päeva. Märgista viaalile lahuse valmistamise kuupäev. Hägused lahused või osakesed ei kõlba.
Segud sisaldavad ühes viaalis mitut toimeainet. Vali peptiidiks lihtsalt segu: kalkulaator näitab lisaks, kui palju igat komponenti sinu süstis on. Mitme eraldi viaali kombinatsiooni jaoks kasuta Stack Builderit.
Ei. Sinu viimased seaded salvestatakse lokaalselt brauserisse ja taastatakse järgmisel külastusel. Arvutusi saad ka ajaloost tagasi kutsuda, protokollina salvestada või lingina jagada.
Vali peptiid, et avada selle kalkulaatorileht eeltäidetud väärtustega.
Arvuta iga peptiidi jaoks täpsed lahuse mahud, insuliiniühikud ja annuste arv viaali kohta.
Viaal, vesi ja annus on teada
Ühikud mõõdavad mahtu, mitte toimeainet. 10 IU = 0,10 ml. Mitu mg selles on, sõltub segust. Kalkulaator on selle sinu eest välja arvutanud.
Peaaegu kõik insuliinisüstlad on U-100. Vali U-40 ainult siis, kui süstal on tähistatud U-40.
Lingitud allikad viivad PubMedisse ja avanevad uuel vahelehel.
Tesamorelin is a synthetic analog of human growth hormone-releasing hormone (GHRH). It consists of the full 44 amino acids of native GHRH(1-44), with the N-terminus modified by a trans-3-hexenoic acid group. This modification protects the molecule from rapid enzymatic degradation by dipeptidyl peptidase-4 (DPP-4), substantially extending its biological stability compared to unmodified GHRH. Tesamorelin carries the research designation TH9507 and is known in the pharmaceutical literature under the trade name Egrifta.
Unlike ghrelin-type growth hormone secretagogues such as Ipamorelin, Tesamorelin acts directly on the GHRH receptor in the pituitary gland. It mimics the body's own signal that prompts the somatotroph cells of the pituitary to release growth hormone (GH). Tesamorelin therefore does not introduce growth hormone from outside the body — it amplifies the body's own, pulsatile GH production. This mechanism largely preserves the physiological feedback of the hypothalamic-pituitary axis, which distinguishes Tesamorelin from the direct administration of recombinant GH.
Tesamorelin has been studied most extensively in clinical trials of HIV-associated lipodystrophy, a condition characterized by an accumulation of visceral abdominal fat. The registration trials by Falutz and colleagues demonstrated a meaningful reduction in visceral adipose tissue, making Tesamorelin one of the few GHRH peptides with a robust human clinical dataset. In peptide research, it is discussed primarily for its targeted effect on the visceral fat depot and its well-characterized pharmacokinetics.
Tesamorelin exerts its biological effects through the GHRH receptor axis and the downstream GH-IGF-1 cascade. The key mechanisms can be summarized as follows:
In research settings, Tesamorelin is typically administered subcutaneously once daily, preferably in the evening to support nocturnal GH release. A slow titration ramp is not strictly required, but starting at the lower end of the dose range is a sensible precaution to observe tolerability, particularly potential fluid retention.
A common vial size is 20 mg. Adding 2 mL of bacteriostatic water gives a concentration of 10 mg/mL (10,000 mcg/mL).
At 1 mg per day, a 20 mg vial provides 20 days of dosing (10 days at 2 mg per day). The smaller 10 mg vial reconstituted with 2 mL yields 5 mg/mL (5,000 mcg/mL) and provides ten single 1 mg doses. Use the Tesamorelin calculator above to compute exact volumes for any vial size, reconstitution volume, and target dose.
Tesamorelin is administered subcutaneously into the subcutaneous fat layer, most commonly into the abdomen in the area around the navel. Injection sites should be rotated from day to day to avoid localized irritation and tissue hardening. A very short half-life of roughly 30 minutes means the peptide acts quickly and clears quickly, which is why consistent daily administration is important for a stable research protocol.
Tesamorelin is supplied as a lyophilized (freeze-dried) powder in sealed vials and must be reconstituted with bacteriostatic water (BAC water) before use. BAC water contains 0.9% benzyl alcohol, which inhibits microbial growth and extends the usable window of the reconstituted solution. Sterile water for injection is not suitable for multi-dose vials because it offers no preservative.
If the solution appears cloudy, discolored, or contains visible particulate matter, discard the vial and do not inject it.
Tesamorelin has been studied in controlled clinical trials lasting more than a year and showed an overall manageable tolerability profile. However, because its effects are mediated by enhanced growth hormone and IGF-1 activity, the observable effects are closely linked to the known actions of the GH axis. All use remains in the research domain.
At standard research doses, Tesamorelin was described as largely well tolerated in the registration trials. Nonetheless, given its effect on the endocrine GH axis, caution is warranted and consultation with a qualified healthcare provider is strongly recommended.
Tesamorelin belongs to the family of GHRH analogs and is closely related functionally to Sermorelin and CJC-1295 (no DAC). All three stimulate the same GHRH receptor but differ in stability and duration of action. Sermorelin corresponds to the shorter GHRH(1-29) fragment, CJC-1295 without DAC is a modified fragment with improved stability, and Tesamorelin is a fully stabilized GHRH(1-44) analog with the most extensive clinical evidence base for visceral fat reduction.
A widely used concept in research combines a GHRH analog with a GHRP (growth hormone releasing peptide) such as Ipamorelin. The two peptides act through distinct, complementary receptors:
Because such a combined stimulus places greater demand on the GH-IGF-1 axis, research protocols typically favor conservative doses, careful monitoring of glucose and IGF-1, and planned breaks.
Owing to its specific clinical profile — the targeted reduction of visceral adipose tissue — Tesamorelin is often used as a standalone compound in research rather than being stacked. Its clearly defined endpoint of visceral fat reduction makes it a readily studyable single peptide with unambiguous biomarkers such as IGF-1 and VAT measurement.
Research-grade Tesamorelin is available directly from BergdorfBio: Tesamorelin at BergdorfBio.
Tesamorelin is not growth hormone — it is a GHRH analog. It prompts the pituitary to release more of the body's own growth hormone, whereas HGH supplies the hormone directly from outside the body. The key difference lies in feedback: with Tesamorelin, the inhibitory action of somatostatin is preserved, so GH levels cannot rise without limit. In addition, the natural pulsatile secretion pattern of growth hormone is maintained, which is not the case with constant HGH administration.
The body's largest natural GH release occurs during the first hours of deep sleep. An evening injection of Tesamorelin is intended to amplify this physiological pulse rather than create an additional, off-rhythm GH surge. The very short half-life of roughly 30 minutes fits this concept well, since the signal remains tightly time-limited.
IGF-1, used as a biomarker, rises measurably within the first days to weeks. The structural changes — in particular the reduction of visceral adipose tissue — develop considerably more slowly. In the registration trials, significant changes in visceral abdominal fat were typically documented only after several months of continuous use.
Because growth hormone and insulin act in partly opposing ways, a high insulin level after a carbohydrate-rich meal dampens the GH response. Research protocols therefore often suggest spacing the injection some time away from the last large meal. With an evening administration before bed, this gap often arises naturally.
Growth hormone can reduce insulin sensitivity, so Tesamorelin can influence fasting blood glucose and glucose tolerance. In studies, these effects were generally moderate and dose-dependent. Monitoring glucose values is sensible for longer research protocols, particularly in individuals with pre-existing insulin resistance.
Tesamorelin does not act on the hypothalamic-pituitary-gonadal axis and does not suppress the body's own testosterone production. A classic PCT, of the kind common after androgenic compounds, is therefore not required. Because Tesamorelin merely amplifies the natural GHRH signal, the pituitary generally recovers after discontinuation without further intervention.
Yes. As a growth hormone-releasing factor and GH secretagogue, Tesamorelin falls under the WADA prohibited list and is banned in sport both in-competition and out-of-competition. Athletes subject to WADA-compliant testing should treat Tesamorelin as a prohibited substance and verify the applicable anti-doping rules before any use.
Some research protocols combine a GHRH analog and a GHRP in a single syringe immediately before injection. In general, however, it is safer to reconstitute each peptide individually and inject them separately, since their combined stability in solution is not well characterized. Separate injections at adjacent sites add minimal inconvenience and eliminate the risk of dosing errors.
BergdorfBio offers research-grade Tesamorelin with verified purity and concentration. View the product page: Buy Tesamorelin at BergdorfBio. All products are sold strictly for research purposes.
Medical Disclaimer: The information on this page is provided for educational and research purposes only. Within the context of this offering, Tesamorelin is not an approved drug or medical treatment and is sold strictly for research use. Nothing on this page constitutes medical advice, diagnosis, or a recommendation to use any specific compound. Always consult a qualified healthcare professional before beginning any peptide protocol. BergdorfBio assumes no liability for the use or misuse of the information presented here.
Pulbrist valmis süstlani viie sammuga. Ülalolev kalkulaator annab kogused automaatselt.
Lase viaalil ja veel jõuda toatemperatuurini. Pühi mõlemad kummikorgid alkoholilapiga.
Tõmba kalkulaatori soovitatud BAC-vee kogus suurema süstlaga.
Lase veel voolata mööda peptiidiviaali siseseina, ära pihusta seda otse pulbrile.
Keeruta viaali õrnalt, ära raputa. Pulber lahustub selgeks 1-2 minuti jooksul.
Tõmba insuliinisüstlaga täpselt arvutatud kriipsuni. Valmis.
Tavalised algväärtused orienteerumiseks. Iga rida avab selle peptiidi kalkulaatori.
| Peptiid | Kategooria | Tavaline annus | Viaalisuurused | BAC (algus) | Saadaval | Arvuta |
|---|---|---|---|---|---|---|
| VIP | Neuropeptiidide uurimine | - | 10 mg | 2 ml | Ainult kalkulaator | Arvuta |
| Retatrutide | GLP-1/GIP/GCG | 0,5-12 mg | 2 / 5 / 10 / 15 mg | 2 ml | Ainult kalkulaator | Arvuta |
| Cagrilintide | Amüliini analoog | - | 5 mg | 2 ml | Ainult kalkulaator | Arvuta |
| Semaglutide | GLP-1 | 0,25-2,4 mg | 2 / 5 / 10 mg | 2 ml | Ainult kalkulaator | Arvuta |
| Tirzepatide | GLP-1/GIP | 2,5-15 mg | 10 / 15 / 20 / 30 / 60 / 90 mg | 2 ml | Ainult kalkulaator | Arvuta |
| GHK-Cu | Vaskepeptiid | 1-4 mg | 10 / 20 / 50 mg | 5 ml | Ainult kalkulaator | Arvuta |
| AHK-Cu | Vaskepeptiid | - | 100 mg | 5 ml | Ainult kalkulaator | Arvuta |
| BPC-157 | Kudede taastamine | 0,2-0,5 mg | 2 / 5 / 10 mg | 2 ml | Ainult kalkulaator | Arvuta |
| TB-500 | Thymosin Beta-4 | 2-5 mg | 2 / 5 / 10 mg | 2 ml | Ainult kalkulaator | Arvuta |
| CJC-1295 (ilma DAC-ta) | GHRH analoog | 100-200 mcg | 2 / 5 / 10 mg | 2 ml | Ainult kalkulaator | Arvuta |
| Ipamorelin | GHRP | 200-300 mcg | 2 / 5 mg | 2 ml | Ainult kalkulaator | Arvuta |
| AOD-9604 | Rasvade ainevahetus | 250-500 mcg | 2 / 5 mg | 2 ml | Ainult kalkulaator | Arvuta |
| PT-141 | Bremelanotide | - | 2 / 5 / 10 mg | 2 ml | Ainult kalkulaator | Arvuta |
| MOTS-c | Mitokondriaalne | 5-10 mg | 5 / 10 mg | 2 ml | Ainult kalkulaator | Arvuta |
| Selank | Anksiolüütiline | 150-500 mcg | 2 / 5 / 10 mg | 2 ml | Ainult kalkulaator | Arvuta |
| SS-31 | Elamipretide | 0,1-1 mg | 5 / 10 mg | 2 ml | Ainult kalkulaator | Arvuta |
| Glow Stack | Stack | 0,5-2 mg | 70 mg | 3 ml | Ainult kalkulaator | Arvuta |
| Klow Stack | Stack | 0,5-2 mg | 55 mg | 3 ml | Ainult kalkulaator | Arvuta |
| Melanotan II | Melanokortiin | 100-1000 mcg | 5 / 10 mg | 2 ml | Ainult kalkulaator | Arvuta |
| Melanotan I | Melanokortiin | - | 5 / 10 mg | 2 ml | Ainult kalkulaator | Arvuta |
| Sermorelin | GHRH analoog | 50-300 mcg | 5 mg | 2 ml | Ainult kalkulaator | Arvuta |
| Tesamorelin | GHRH analoog | 1-2 mg | 10 / 20 mg | 2 ml | Ainult kalkulaator | Arvuta |
| Thymosin Alpha-1 | Tüümusepetiid | 0,8-3,2 mg | 1.6 / 5 / 10 mg | 1 ml | Ainult kalkulaator | Arvuta |
| Epithalon | Pikaajalisus | 2-10 mg | 10 / 20 / 50 mg | 2 ml | Ainult kalkulaator | Arvuta |
| KPV | Immuunsüsteem / barjäär | 100-1000 mcg | 5 / 10 mg | 2 ml | Ainult kalkulaator | Arvuta |
| HGH Fragment 176-191 | Metaboolne fragment | 100-500 mcg | 2 / 5 / 10 mg | 2 ml | Ainult kalkulaator | Arvuta |
| Semax | Kognitiivne | 100-1000 mcg | 10 / 30 mg | 2 ml | Ainult kalkulaator | Arvuta |
| N-Acetyl Semax | Kognitiivne | 100-1000 mcg | 5 / 10 mg | 2 ml | Ainult kalkulaator | Arvuta |
| Hexarelin | GHRP | 50-200 mcg | 2 / 5 mg | 2 ml | Ainult kalkulaator | Arvuta |
| GHRP-6 | GHRP | 50-300 mcg | 2 / 5 mg | 2 ml | Ainult kalkulaator | Arvuta |
| GHRP-2 | GHRP | 50-250 mcg | 2 / 5 mg | 2 ml | Ainult kalkulaator | Arvuta |
| DSIP | Uni | 50-500 mcg | 10 mg | 2 ml | Ainult kalkulaator | Arvuta |
| 5-Amino-1MQ | Metaboolne | 2,5-10 mg | 10 mg | 2 ml | Ainult kalkulaator | Arvuta |
| Pinealon | Uurimispeptiid | - | 10 mg | 2 ml | Ainult kalkulaator | Arvuta |
| Survodutide | GLP-1/glükagoon | - | 10 mg | 2 ml | Ainult kalkulaator | Arvuta |
| Kisspeptin-10 | KISS1R / GPR54 | - | 10 mg | 2 ml | Ainult kalkulaator | Arvuta |
| HGH 191AA | Kasvuhormoon | 1-5 mg | 10 mg | 1 ml | Ainult kalkulaator | Arvuta |
| NAD+ | Pikaajalisus / kofaktor | 100-500 mg | 1000 mg | 10 ml | Ainult kalkulaator | Arvuta |
Väärtused on mõeldud orienteerumiseks uurimiskontekstis ega asenda professionaalset nõuannet.
Kontsentratsiooni ja süstemahu õige arvutamine tundub tühine, kuid on kõige sagedasem veaallikas. Isegi 10 % suurune arvutusviga lahuse valmistamisel tähendab, et saad kas liiga vähe toimeainet või manustad kogemata üleannuse.
Lüofiliseeritud peptiide müüakse milligrammides ja need lahustatakse bakteriostaatilises vees (BAC-vesi). Peptiidi ja vee suhe määrab kontsentratsiooni ja sellest tuleneb, mitu ühikut insuliinisüstlale tõmbad. Insuliinisüstlaid gradueeritakse ühikutes, mitte milligrammides. Kalkulaator teeb selle ümberarvutuse ära, sealhulgas mõistlikkuse kontrolli kõige ohtlikuma vea vastu: mg ja mcg segiajamine.
Milligramm (mg) on ühik, milles lüofiliseeritud peptiide müüakse, näiteks „5 mg BPC-157". Mikrogramm (mcg) mõõdab üksikannust, näiteks „250 mcg süsti kohta". 1 mg = 1000 mcg. Kalkulaator teeb ümberarvutuse automaatselt ja hoiatab, kui sisestus tundub segiaetud olevat.
U-100 tähendab, et süstal on kalibreeritud 100 ühikule milliliitri kohta. 100 IU = 1 ml, seega 10 IU = 0,10 ml, sõltumata sellest, mis süstlas on. IU arvutus põhineb täpselt sellel seosel.
Palju peptiidi ja vähe vett teeb lahuse väga kontsentreerituks, mistõttu maht annuse kohta on tilluke ja raskesti loetav. Kasuta segamise abivahendit: see leiab veekoguse, millega tekib puhas ja hästi loetav kriips.
Külmkapis 2-8 °C juures tavaliselt 21-30 päeva. Märgista viaalile lahuse valmistamise kuupäev. Hägused lahused või osakesed ei kõlba.
Segud sisaldavad ühes viaalis mitut toimeainet. Vali peptiidiks lihtsalt segu: kalkulaator näitab lisaks, kui palju igat komponenti sinu süstis on. Mitme eraldi viaali kombinatsiooni jaoks kasuta Stack Builderit.
Ei. Sinu viimased seaded salvestatakse lokaalselt brauserisse ja taastatakse järgmisel külastusel. Arvutusi saad ka ajaloost tagasi kutsuda, protokollina salvestada või lingina jagada.
Vali peptiid, et avada selle kalkulaatorileht eeltäidetud väärtustega.
Laos
Laos
Vaata toodet
TesamorelinVaata toodet
TesamorelinTavalised algväärtused orienteerumiseks. Iga rida avab selle peptiidi kalkulaatori.
| Peptiid | Kategooria | Tavaline annus | Viaalisuurused | BAC (algus) | Saadaval | Arvuta |
|---|---|---|---|---|---|---|
| VIP | Neuropeptiidide uurimine | - | 10 mg | 2 ml | Laos | Arvuta |
| Retatrutide | GLP-1/GIP/GCG | 0,5-12 mg | 2 / 5 / 10 / 15 mg | 2 ml | Laos | Arvuta |
| Cagrilintide | Amüliini analoog | - | 5 mg | 2 ml | Laos | Arvuta |
| Tirzepatide | GLP-1/GIP | 2,5-15 mg | 10 / 15 / 20 / 30 / 60 / 90 mg | 2 ml | Laos | Arvuta |
| GHK-Cu | Vaskepeptiid | 1-4 mg | 10 / 20 / 50 mg | 5 ml | Laos | Arvuta |
| AHK-Cu | Vaskepeptiid | - | 100 mg | 5 ml | Laos | Arvuta |
| BPC-157 | Kudede taastamine | 0,2-0,5 mg | 2 / 5 / 10 mg | 2 ml | Laos | Arvuta |
| TB-500 | Thymosin Beta-4 | 2-5 mg | 2 / 5 / 10 mg | 2 ml | Laos | Arvuta |
| CJC-1295 (ilma DAC-ta) | GHRH analoog | 100-200 mcg | 2 / 5 / 10 mg | 2 ml | Laos | Arvuta |
| Ipamorelin | GHRP | 200-300 mcg | 2 / 5 mg | 2 ml | Laos | Arvuta |
| PT-141 | Bremelanotide | - | 2 / 5 / 10 mg | 2 ml | Laos | Arvuta |
| MOTS-c | Mitokondriaalne | 5-10 mg | 5 / 10 mg | 2 ml | Laos | Arvuta |
| Selank | Anksiolüütiline | 150-500 mcg | 2 / 5 / 10 mg | 2 ml | Laos | Arvuta |
| SS-31 | Elamipretide | 0,1-1 mg | 5 / 10 mg | 2 ml | Laos | Arvuta |
| Glow Stack | Stack | 0,5-2 mg | 70 mg | 3 ml | Laos | Arvuta |
| Klow Stack | Stack | 0,5-2 mg | 55 mg | 3 ml | Laos | Arvuta |
| Melanotan II | Melanokortiin | 100-1000 mcg | 5 / 10 mg | 2 ml | Laos | Arvuta |
| Melanotan I | Melanokortiin | - | 5 / 10 mg | 2 ml | Laos | Arvuta |
| Sermorelin | GHRH analoog | 50-300 mcg | 5 mg | 2 ml | Laos | Arvuta |
| Tesamorelin | GHRH analoog | 1-2 mg | 10 / 20 mg | 2 ml | Laos | Arvuta |
| Thymosin Alpha-1 | Tüümusepetiid | 0,8-3,2 mg | 1.6 / 5 / 10 mg | 1 ml | Laos | Arvuta |
| Epithalon | Pikaajalisus | 2-10 mg | 10 / 20 / 50 mg | 2 ml | Laos | Arvuta |
| KPV | Immuunsüsteem / barjäär | 100-1000 mcg | 5 / 10 mg | 2 ml | Laos | Arvuta |
| Semax | Kognitiivne | 100-1000 mcg | 10 / 30 mg | 2 ml | Laos | Arvuta |
| DSIP | Uni | 50-500 mcg | 10 mg | 2 ml | Laos | Arvuta |
| 5-Amino-1MQ | Metaboolne | 2,5-10 mg | 10 mg | 2 ml | Laos | Arvuta |
| Pinealon | Uurimispeptiid | - | 10 mg | 2 ml | Laos | Arvuta |
| Survodutide | GLP-1/glükagoon | - | 10 mg | 2 ml | Laos | Arvuta |
| Kisspeptin-10 | KISS1R / GPR54 | - | 10 mg | 2 ml | Laos | Arvuta |
| NAD+ | Pikaajalisus / kofaktor | 100-500 mg | 1000 mg | 10 ml | Laos | Arvuta |
| Semaglutide | GLP-1 | 0,25-2,4 mg | 2 / 5 / 10 mg | 2 ml | Ainult kalkulaator | Arvuta |
| AOD-9604 | Rasvade ainevahetus | 250-500 mcg | 2 / 5 mg | 2 ml | Ainult kalkulaator | Arvuta |
| HGH Fragment 176-191 | Metaboolne fragment | 100-500 mcg | 2 / 5 / 10 mg | 2 ml | Ainult kalkulaator | Arvuta |
| N-Acetyl Semax | Kognitiivne | 100-1000 mcg | 5 / 10 mg | 2 ml | Ainult kalkulaator | Arvuta |
| Hexarelin | GHRP | 50-200 mcg | 2 / 5 mg | 2 ml | Ainult kalkulaator | Arvuta |
| GHRP-6 | GHRP | 50-300 mcg | 2 / 5 mg | 2 ml | Ainult kalkulaator | Arvuta |
| GHRP-2 | GHRP | 50-250 mcg | 2 / 5 mg | 2 ml | Ainult kalkulaator | Arvuta |
| HGH 191AA | Kasvuhormoon | 1-5 mg | 10 mg | 1 ml | Ainult kalkulaator | Arvuta |
Väärtused on mõeldud orienteerumiseks uurimiskontekstis ega asenda professionaalset nõuannet.
Tavalised algväärtused orienteerumiseks. Iga rida avab selle peptiidi kalkulaatori.
| Peptiid | Kategooria | Tavaline annus | Viaalisuurused | BAC (algus) | Saadaval | Arvuta |
|---|---|---|---|---|---|---|
| VIP | Neuropeptiidide uurimine | - | 10 mg | 2 ml | Laos | Arvuta |
| Retatrutide | GLP-1/GIP/GCG | 0,5-12 mg | 2 / 5 / 10 / 15 mg | 2 ml | Laos | Arvuta |
| Cagrilintide | Amüliini analoog | - | 5 mg | 2 ml | Laos | Arvuta |
| Tirzepatide | GLP-1/GIP | 2,5-15 mg | 10 / 15 / 20 / 30 / 60 / 90 mg | 2 ml | Laos | Arvuta |
| GHK-Cu | Vaskepeptiid | 1-4 mg | 10 / 20 / 50 mg | 5 ml | Laos | Arvuta |
| AHK-Cu | Vaskepeptiid | - | 100 mg | 5 ml | Laos | Arvuta |
| BPC-157 | Kudede taastamine | 0,2-0,5 mg | 2 / 5 / 10 mg | 2 ml | Laos | Arvuta |
| TB-500 | Thymosin Beta-4 | 2-5 mg | 2 / 5 / 10 mg | 2 ml | Laos | Arvuta |
| CJC-1295 (ilma DAC-ta) | GHRH analoog | 100-200 mcg | 2 / 5 / 10 mg | 2 ml | Laos | Arvuta |
| Ipamorelin | GHRP | 200-300 mcg | 2 / 5 mg | 2 ml | Laos | Arvuta |
| PT-141 | Bremelanotide | - | 2 / 5 / 10 mg | 2 ml | Laos | Arvuta |
| MOTS-c | Mitokondriaalne | 5-10 mg | 5 / 10 mg | 2 ml | Laos | Arvuta |
| Selank | Anksiolüütiline | 150-500 mcg | 2 / 5 / 10 mg | 2 ml | Laos | Arvuta |
| SS-31 | Elamipretide | 0,1-1 mg | 5 / 10 mg | 2 ml | Laos | Arvuta |
| Glow Stack | Stack | 0,5-2 mg | 70 mg | 3 ml | Laos | Arvuta |
| Klow Stack | Stack | 0,5-2 mg | 55 mg | 3 ml | Laos | Arvuta |
| Melanotan II | Melanokortiin | 100-1000 mcg | 5 / 10 mg | 2 ml | Laos | Arvuta |
| Melanotan I | Melanokortiin | - | 5 / 10 mg | 2 ml | Laos | Arvuta |
| Sermorelin | GHRH analoog | 50-300 mcg | 5 mg | 2 ml | Laos | Arvuta |
| Tesamorelin | GHRH analoog | 1-2 mg | 10 / 20 mg | 2 ml | Laos | Arvuta |
| Thymosin Alpha-1 | Tüümusepetiid | 0,8-3,2 mg | 1.6 / 5 / 10 mg | 1 ml | Laos | Arvuta |
| Epithalon | Pikaajalisus | 2-10 mg | 10 / 20 / 50 mg | 2 ml | Laos | Arvuta |
| KPV | Immuunsüsteem / barjäär | 100-1000 mcg | 5 / 10 mg | 2 ml | Laos | Arvuta |
| Semax | Kognitiivne | 100-1000 mcg | 10 / 30 mg | 2 ml | Laos | Arvuta |
| DSIP | Uni | 50-500 mcg | 10 mg | 2 ml | Laos | Arvuta |
| 5-Amino-1MQ | Metaboolne | 2,5-10 mg | 10 mg | 2 ml | Laos | Arvuta |
| Pinealon | Uurimispeptiid | - | 10 mg | 2 ml | Laos | Arvuta |
| Survodutide | GLP-1/glükagoon | - | 10 mg | 2 ml | Laos | Arvuta |
| Kisspeptin-10 | KISS1R / GPR54 | - | 10 mg | 2 ml | Laos | Arvuta |
| NAD+ | Pikaajalisus / kofaktor | 100-500 mg | 1000 mg | 10 ml | Laos | Arvuta |
| Semaglutide | GLP-1 | 0,25-2,4 mg | 2 / 5 / 10 mg | 2 ml | Ainult kalkulaator | Arvuta |
| AOD-9604 | Rasvade ainevahetus | 250-500 mcg | 2 / 5 mg | 2 ml | Ainult kalkulaator | Arvuta |
| HGH Fragment 176-191 | Metaboolne fragment | 100-500 mcg | 2 / 5 / 10 mg | 2 ml | Ainult kalkulaator | Arvuta |
| N-Acetyl Semax | Kognitiivne | 100-1000 mcg | 5 / 10 mg | 2 ml | Ainult kalkulaator | Arvuta |
| Hexarelin | GHRP | 50-200 mcg | 2 / 5 mg | 2 ml | Ainult kalkulaator | Arvuta |
| GHRP-6 | GHRP | 50-300 mcg | 2 / 5 mg | 2 ml | Ainult kalkulaator | Arvuta |
| GHRP-2 | GHRP | 50-250 mcg | 2 / 5 mg | 2 ml | Ainult kalkulaator | Arvuta |
| HGH 191AA | Kasvuhormoon | 1-5 mg | 10 mg | 1 ml | Ainult kalkulaator | Arvuta |
Väärtused on mõeldud orienteerumiseks uurimiskontekstis ega asenda professionaalset nõuannet.
Vali peptiid, et avada selle kalkulaatorileht eeltäidetud väärtustega.
Vali peptiid, et avada selle kalkulaatorileht eeltäidetud väärtustega.